Preparation and application of new and old metabolites (4S) and (4R) - 4 - (4-cyano-2-methoxyphenyl) - 5-etoxi-2, 8-dimethyl-1, 4-dihydro-1, 6-naftiridina-3-carboxamida
Procedures for the preparation of formulated compounds: m1a (s) and M1B (R)；M2A (s) and M2b (R)；M3a (s) and m3b (R)；The corresponding compounds were separated by chromatography during the operation. These are (4S) - and (4R) - 4 - (4-cyano-2-methoxy) - 5-etoxi-2,8-dimethyl-1,4-dihydro-1,6-nafturidina-3-carboxamida, the new and old metabolites of (4S) - and (4R) - 4 - (4-cyano-2-methoxy), are antagonists of ore molecular receptors and are therefore suitable for the treatment and / or prevention of disorders associated with concentration changes. Plasma aldehydes, such as hyperaldehyde； edema, such as pulmonary edema； renal failure, such as acute and chronic renal failure； and so on.Referido a procedimientos para la preparacion de compuestos de formulas: M1a (S) y M1b (R)； M2a (S) y M2b (R)； M3a (S) y M3b (R)； estos enantiomeros se separan mediante procedimientos cromatograficos en una fase quiral. Estos son metabolitos de (4s)- y (4R)-4-(4- ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida, y actuan como antagonistas del receptor de mineralocorticoides, por lo que son apropiados para su uso como medicamentos para el tratamiento y/o profilaxis de trastornos relacionados por la variacion en la concentracion de aldosterona en plasma, como hiperaldosteronismo； en la formacion de edemas, como edema pulmonar； trastornos renales, como insuficiencia renal aguda y cronica； entre otros.
